Unfortunately, SERMs and AIs are only effective for preventing estrogen receptor positive cancers and are associated with poor compliance and significant adverse effects, including thromboembolic events and endometrial cancer [4,5,6,7,8]. The gene discussed is ESR1; the disease is cancer.